Rhinitis/rhinorrhea (intranasal products):

Indications for: RYALTRIS

Seasonal allergic rhinitis.

Adult Dosage:

Use 2 sprays in each nostril twice daily.

Children Dosage:

<12yrs: not established.

RYALTRIS Warnings/Precautions:

Risk of epistaxis, nasal ulcerations, nasal septal perforations, impaired nasal wound healing, local Candida infections; monitor periodically. Recent nasal septal ulcers, nasal surgery, or nasal trauma: avoid until healing has occurred. Discontinue if Candida infections or hypersensitivity reactions occur. Monitor closely if change in vision or those with a history of increased intraocular pressure, glaucoma, and/or cataracts. Immunosuppression. Respiratory tract tuberculosis. Infections (eg, fungal, bacterial, viral, ocular herpes simplex). If exposed to measles or chickenpox, may need immunoglobulin or VZIG prophylactic therapy. Hypercorticism. Adrenal suppression. Monitor routinely for growth in children. Hepatic impairment. Pregnancy. Nursing mothers.

RYALTRIS Classification:

Antihistamine + corticosteroid.

RYALTRIS Interactions:

Avoid concomitant alcohol or other CNS depressants. Caution with strong CYP3A4 inhibitors (eg, ketoconazole).

Adverse Reactions:

Dysgeusia, epistaxis, nasal discomfort; somnolence, impaired mental alertness.


Olopatadine is not extensively metabolized.

Drug Elimination:

Olopatadine: renal (~70%), fecal (~17%).  Half-life: 9 hours (olopatadine); 18 hours (mometasone furoate).

Generic Drug Availability:


How Supplied:

Spray—29g (240 sprays)